Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. - Wikidata - awgldk - TriplyDB

Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.

Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.

http://www.wikidata.org/entity/Q37703392

about

The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy γδ T Cell Immunotherapy-A Review An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol Surgical immune interventions for solid malignancies.Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.Quantum dot-based multiplexed imaging in malignant ascites: a new model for malignant ascites classification.Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.Rapid cloning, expression, and functional characterization of paired αβ and γδ T-cell receptor chains from single-cell analysis.Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.2015 Guidance on cancer immunotherapy development in early-phase clinical studies.In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.Myeloid molecular characteristics of human γδ T cells support their acquisition of tumor antigen-presenting capacity.Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development.Current Advances in γδ T Cell-Based Tumor Immunotherapy.Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug.Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect.Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer

P2860

Q26859775-11C901E1-2B06-454F-A7F5-0EE04926B3B6 Q26995102-5CCDBE32-DE89-4AAC-8F03-EB847E20F5F8 Q28603645-D38EA058-4200-41FB-BFA3-999E29C1FE38 Q30393261-F30DB9DB-9E1F-400B-80D4-C8E03396B706 Q33920919-7CC4C89C-E96B-48ED-8644-C4DB8C61F705 Q35168709-2F2D7BA7-D3C5-4236-891A-D7DCE30F0F16 Q35641721-6CFC4B9F-33DA-4EA4-B1D4-78873684D35E Q35917978-2C8C45C2-3513-4172-A4F7-5EDCBAFB4BD0 Q36123941-E21049C5-DD01-467A-B111-C1AD23C9CB2D Q36467378-8A7253E7-3A14-4F06-B53B-109DDF38EE71 Q37354985-90C4FC69-97F9-42E6-9521-2E535CB419FB Q37655345-D05F9E0C-41C7-43E5-B8BC-8CF39A0EE307 Q38730126-9F9E8FEF-1D72-414F-ACC2-E6157E5B2772 Q38883322-AFD3ACAE-F74B-499C-A1CE-DA2AD3DF3E83 Q41110505-73C51A3F-473B-4264-BC52-5645A741829D Q47100174-D860DAFC-5C3A-429C-B543-B2FEA022051D Q47666620-0D2A8507-0903-47FA-AFCD-93E7E1920BC6 Q55311835-E00F5DC0-558C-4BFD-B81E-1989396DA66B Q55430421-7F9272BA-8FE8-4957-8D67-E90916231ECA Q57167306-EC18ABE6-B69F-4BA3-846E-8CE3C9A6F02F

P2860

Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.

http://www.wikidata.org/entity/Q37703392

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Intraperitoneal injection of i ...... ascites due to gastric cancer.

@en

Intraperitoneal injection of i ...... ascites due to gastric cancer.

@nl

type

label

Intraperitoneal injection of i ...... ascites due to gastric cancer.

@en

Intraperitoneal injection of i ...... ascites due to gastric cancer.

@nl

prefLabel

Intraperitoneal injection of i ...... ascites due to gastric cancer.

@en

Intraperitoneal injection of i ...... ascites due to gastric cancer.

@nl

P1433

Q37703392-7D510B5D-667C-4DC3-9CE3-14E4E9536A73

P1476

Q37703392-B9A641BB-28EB-444E-8409-9342AC8AE0CA

P2093

Q37703392-03CFE7D7-C370-41C8-881A-730D02C43DD1

Q37703392-0411DFEA-086B-465A-A740-620B63486111

Q37703392-05FD7159-05B8-4836-BA4F-A1679DFABABB

Q37703392-26DE5385-7BF6-4C62-B280-C23212AE3CF6

Q37703392-8FC1CA47-E75A-4833-92EA-01892CE3AE7A

Q37703392-C03B4BB4-9A2A-4A0E-A8FA-4B39E86147EB

Q37703392-C045E15E-F69E-4EAA-95D4-20BB4D158828

P2860

Q37703392-0142F13A-4034-41BE-A95C-A137911C417D

Q37703392-014EC182-3641-4E58-93AC-F3AEDCEFF48F

Q37703392-087AD758-99C9-46B0-B256-69707FBF7942

Q37703392-26EA4A26-5C62-4993-9C06-35B6AF28CCE3

Q37703392-2BDE7760-64C8-4686-A4C9-00E6D02FDE0F

Q37703392-31B10BC0-A8CC-4F38-B4BF-3C104A5752A3

Q37703392-321847BB-9870-4FDB-89D8-1819601EC4A5

Q37703392-32866737-990F-459A-8CA5-C6162318D789

Q37703392-38BD48AB-CD24-49A9-A771-951E2C2065A8

Q37703392-3A57A7E3-C53D-4642-A160-406FD848A9E3

P304

Q37703392-0D3926D4-5945-4841-8019-D0DAB7360426

P31

Q37703392-95A78465-8395-4F0E-8F04-A0AC915A0B43

P356

Q37703392-471D1188-F936-4B1E-B891-9CAAF6739BDD

P407

Q37703392-45CDDDF7-E484-4DDE-8029-99DC126DD93C

P433

Q37703392-E231AAB4-2387-4806-A32E-A7D1261898A3

P478

Q37703392-D36C6924-BC06-42A4-B576-FDBC85082A5E

P50

Q37703392-79E5118F-7644-4EC8-B0D4-95A76174A6AF

Q37703392-904E3310-BB28-45AE-A219-42F002FCC71D

P577

Q37703392-F164DA40-9122-490E-BBE9-C8251A3976E0

P5875

Q37703392-3505C106-0AA3-41FF-95AA-3CD90D848558

P698

Q37703392-E896AE6D-CCB4-460B-B701-8D50A0C2C4FA

P932

Q37703392-DCD5A1F3-53EE-440E-B732-6009E08604B6

P356

P1433

Cancer Medicine

P1476

Intraperitoneal injection of i ...... ascites due to gastric cancer

@en

P2093

Hirokazu Matsushita

http://www.w3.org/2001/XMLSchema#string

Ikuo Wada

http://www.w3.org/2001/XMLSchema#string

Kazuhiko Mori

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Kakimi

http://www.w3.org/2001/XMLSchema#string

Nobuyuki Shimizu

http://www.w3.org/2001/XMLSchema#string

Shuichi Noji

http://www.w3.org/2001/XMLSchema#string

Yasuyuki Seto

http://www.w3.org/2001/XMLSchema#string

P2860

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

[gamma][delta] cells: a right time and a right place for a conserved third way of protection

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Malignant ascites: pathophysiology and treatment.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Gammadelta T cells: functional plasticity and heterogeneity.

Innate T-cell immunity in HIV infection: the role of Vgamma9Vdelta2 T lymphocytes.

Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells

P304

362-375

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.196

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Hiroharu Yamashita

P577

2014-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260154417

http://www.w3.org/2001/XMLSchema#string

P698

24515916

http://www.w3.org/2001/XMLSchema#string

P932

3987085

http://www.w3.org/2001/XMLSchema#string